What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a neutral rating to a sell rating in a report released on Friday, Marketbeat Ratings reports. Citigroup currently has $25.

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.

Ratings for Hims & Hers Health HIMS were provided by 12 analysts in the past three months, showcasing a mix of bullish and ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

OpenAI CEO Sam Altman and Meta both announced $1 million donations, and Amazon and Apple CEO Tim Cook have also reportedly ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Cedar Grove Capital Management, an investment management company, released its fourth quarter 2024 investor letter. A copy of ...